IBA Receives FDA Approval of its New Compact Gantry Clearing the Way for Proteus®ONE - NEWS10 ABC: Albany, New York News, Weather, Sports

IBA Receives FDA Approval of its New Compact Gantry Clearing the Way for Proteus®ONE

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE IBA sa

LOUVAIN-LA-NEUVE, Belgium, July 16, 2014 /PRNewswire/ --


IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received Marketing Authorization from the U.S. Food and Drug Administration (FDA) for its Compact Gantry Beam Line (CGBL: FDA 510(k) K132919). IBA anticipates that this regulatory approval will intensify the international interest in Proteus®ONE*, IBA's next generation proton therapy compact system.

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/71400584-IBA-FDA-approval-proteus-one  

Proteus®ONE is IBA's single-room proton therapy system which is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including IBA's Intensity Modulated Proton Therapy (IMPT). IBA created the Proteus®ONE system to allow more patients access to proton therapy globally and has already sold five Proteus®ONE systems in Shreveport, Louisiana (USA), Nice (France), Taiwan (China) and two in Japan.

* Proteus®ONE is the brand name of a new configuration of the Proteus® 235. 


Video: 
     http://www.multivu.com/mnr/71400584-IBA-FDA-approval-proteus-one

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

341 Northern Blvd., Albany, NY 12204

Telephone: 518.436.4822
Fax: 518.426.4792
Email: news@news10.com

Can’t find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 Young Broadcasting of Albany, Inc. A Media General Company.